Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | IDH2 | P48735 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329953 | 0.81 | GAA (0.67) | SMN1; SMN2ALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL20357282 | 0.81 | ALDH1A1 (0.79) | SMN1; SMN2ALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL23406402 | 0.79 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL29636844 | 0.79 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL1813423 | 0.79 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL12653702 | 0.78 | LMNA (0.64) | SMN1; SMN2ALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL10144138 | 0.78 | KDM4E (0.65) | SMN1; SMN2ALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL12653712 | 0.78 | CRHBP (0.71) | SMN1; SMN2ALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL5111331 | 0.77 | LMNA (0.62) | SMN1; SMN2ALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL4548170 | 0.77 | ALDH1A1 (0.63) | SMN1; SMN2ALDH1A1L3MBTL1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932300-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932300-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-9421211-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-23 | — | — | US | disclosed |
| US-9421211-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-23 | — | — | US | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | NSUN2, EIF2AK2, RNGTT | SMN1; SMN2 850/4885ALDH1A1 3464/4885L3MBTL1 462/4885 |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | NSUN2, EIF2AK2, RNGTT | SMN1; SMN2 850/4885ALDH1A1 3464/4885L3MBTL1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.